Building the foundation of fusion energy

Once complete, we expect Chrysalis to be among the largest medical isotope production facilities of molybdenum-99 (Mo-99) in the world. Producing it in the U.S. with fusion-driven technology, our facility will close a supply gap left by end-of-life reactors overseas and ease real shortages for hospitals.

Cassiopeia produces Ilumira, our non-carrier-added lutetium-177 for cancer treatment. Ilumira’s consistently high quality supports precise, reliable dosing for treatment programs worldwide.

Heliopolis is our 47,500 square-foot manufacturing site in Fitchburg, Wis. This is where we design, build and test entire first-of-a-kind fusion systems. Electromagnets, ion sources, tritium handling equipment — if it doesn’t exist yet, we build it here.

Building One runs our radiation effects testing system at approximately 46 trillion fusion reactions per second. Aerospace and defense customers test how their electronics hold up under radiation here, while our radiochemists develop the separation science behind our isotopes and fuel recycling.

Our imaging center uses neutron radiography and CT to see inside components and catch flaws invisible to X-rays. We’re one of a limited number of commercial facilities worldwide that can do this without relying on a nuclear reactor.

Our Isotope Delivery Campus produces and distributes SPECT imaging agents that support millions of diagnostic procedures annually for cardiac, pulmonary, thyroid and other applications for hospitals and imaging centers across North America.